share_log

Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5

Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5

Cowen & Co.將全球血液療法的評級下調至市場表現,將目標股價上調至68.5美元
Benzinga Real-time News ·  2022/08/09 04:58

Cowen & Co. analyst Ritu Baral downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Market Perform and raises the price target from $67 to $68.5.

Cowen & Co. 分析師裏圖·巴拉爾將全球血液療法(納斯達克股票代碼:GBT)的評級從跑贏大盤下調至市場表現,並將目標股價從67美元上調至68.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論